Evidence map›Paper›PMID 37460568›Full record

ArticleScientific reports2023

Explainable ML models for a deeper insight on treatment decision for localized prostate cancer.

Jang Hee Han, Sungyup Lee, Byounghwa Lee, Ock-Kee Baek, Samuel L Washington, Annika Herlemann, Peter E Lonergan, Peter R Carroll, Chang Wook Jeong, Matthew R Cooperberg

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Jang Hee Han *Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea.
Sungyup Lee *Electronics and Telecommunications Research Institute (ETRI), Daejeon, Republic of Korea.
Byounghwa LeeElectronics and Telecommunications Research Institute (ETRI), Daejeon, Republic of Korea.
Ock-Kee BaekElectronics and Telecommunications Research Institute (ETRI), Daejeon, Republic of Korea.
Samuel L WashingtonDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Annika HerlemannDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Peter E LonerganDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Peter R CarrollDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Chang Wook Jeong *Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea. drboss@snu.ac.kr.
Matthew R CooperbergDepartment of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
University of California, San Francisco · USElectronics and Telecommunications Research Institute · KRUCSF Helen Diller Family Comprehensive Cancer Center · USSeoul National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although there are several decision aids for the treatment of localized prostate cancer (PCa), there are limitations in the consistency and certainty of the information provided. We aimed to better understand the treatment decision process and develop a decision-predicting model considering oncologic, demographic, socioeconomic, and geographic factors. Men newly diagnosed with localized PCa between 2010 and 2015 from the Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting database were included (n = 255,837). We designed two prediction models: (1) Active surveillance/watchful waiting (AS/WW), radical prostatectomy (RP), and radiation therapy (RT) decision prediction in the entire cohort. (2) Prediction of AS/WW decisions in the low-risk cohort. The discrimination of the model was evaluated using the multiclass area under the curve (AUC). A plausible Shapley additive explanations value was used to explain the model's prediction results. Oncological variables affected the RP decisions most, whereas RT was highly affected by geographic factors. The dependence plot depicted the feature interactions in reaching a treatment decision. The decision predicting model achieved an overall multiclass AUC of 0.77, whereas 0.74 was confirmed for the low-risk model. Using a large population-based real-world database, we unraveled the complex decision-making process and visualized nonlinear feature interactions in localized PCa.

Indexed as

Prostatic NeoplasmsHumansMaleProstatectomyRiskWatchful Waiting

Identifiers

PMID37460568
PMCPMC10352331
OpenAlexW4384522610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.